This study is not yet accepting patients
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Summary
- Eligibility
- for people ages 2-17 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Sofia Verstraete
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Sofia Verstraete
Associate Professor, Pediatrics, School of Medicine. Authored (or co-authored) 26 research publications
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)
- ID
- NCT05784246
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 60 study participants
- Last Updated